NCT06065072

Brief Summary

This is a prospective comparative study that will be conducted at one clinical site in the United States, in which subjects who sign an informed consent form and fulfil all inclusion and exclusion criteria, will have OCT scans obtained using the test and the predicate devices. There will be two main types of analyses performed as part of this study, including 1) a precision analysis, and 2) an agreement analysis. The precision analyses will be conducted utilizing all complete complements of acceptable scans from the test devices and predicate device for each of the 3 configurations. A complete complement of acceptable scans can be defined as subjects having 3 acceptable replicate scans on each of the 3 devices, at each of the 3 configurations. This is also synonymous with 3 scans for each of the 3 configurations on all 3 devices. If subjects have more than 3 acceptable scans per configuration on a device, only the first 3 will be considered for analyses. The agreement analysis will be conducted utilizing the first set of acceptable scans from each instrument for all overlapping measurement types (for all measurement types two or more of the devices have in common) related to performance endpoints.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
167

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jun 2023

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 23, 2023

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

September 12, 2023

Completed
21 days until next milestone

First Posted

Study publicly available on registry

October 3, 2023

Completed
28 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 31, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 31, 2023

Completed
Last Updated

October 3, 2023

Status Verified

September 1, 2023

Enrollment Period

4 months

First QC Date

September 12, 2023

Last Update Submit

September 26, 2023

Conditions

Outcome Measures

Primary Outcomes (3)

  • Agreement between the test devices and predicate device

    Agreement between each of the test devices and the predicate device will be evaluated by the mean difference and SD, the 95% limits of agreement (LOA), the Bland-Altman plots, and Deming regression for each subject population.

    Through study completion, approximately 4 months

  • Precision of the test devices

    A crossed two-way random-effects analysis of variance (ANOVA) model will be used to estimate the repeatability and reproducibility limits of each scan parameter by subject population and study device (test and predicate device). This ANOVA model will include the configuration, subject, and interaction between configuration and subject as the factors. Repeatability and reproducibility standard deviations, as well as the corresponding coefficient of variations (CVs), will be calculated using this ANOVA model.

    Through study completion, approximately 4 months

  • Safety of the test devices

    Adverse events reported will be listed by subject.

    Through study completion, approximately 4 months

Study Arms (3)

Normal

Device: Optical measurement

Cataract

Device: Optical measurement

Special eye

Device: Optical measurement

Interventions

Optical measurements by optical biometers and an OCT

CataractNormalSpecial eye

Eligibility Criteria

Age22 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Normal subjects (22 years of age or older) Cataract subjects (22 years of age or older), Special eyes subjects (22 years of age or older)

You may qualify if:

  • Male or female subjects 22 years of age or older who have full legal capacity to volunteer on the date the informed consent is signed;
  • Subjects who can follow the instructions by the clinical staff at the clinical site, and can attend examinations on the scheduled examination date;
  • Subjects who agree to participate in the study.
  • Male or female subjects 22 years of age or older who have full legal capacity to volunteer on the date the informed consent is signed;
  • Subjects who can follow the instructions by the clinical staff at the clinical site, and can attend examinations on the scheduled examination date;
  • Subjects who agree to participate in the study;
  • Subjects diagnosed with cataract classified per the LOCS III scale.
  • Male or female subjects 22 years of age or older who have full legal capacity to volunteer on the date the informed consent is signed;
  • Subjects who can follow the instructions by the clinical staff at the clinical site, and can attend examinations on the scheduled examination date;
  • Subjects who agree to participate in the study;
  • Subjects diagnosed with one or both eyes having aphakia, pseudophakia or silicone oil.

You may not qualify if:

  • Subjects unable to tolerate ophthalmic imaging;
  • Subjects who did not take off their contact lenses earlier than 15 minutes prior to the study;
  • Subjects with any current ocular pathology, as determined by self-report and confirmed by the investigator assessment and/or confirmed by the investigator assessment at the study visit;
  • Subjects that present with an active ocular infection in either eye;
  • Subjects who have a history of ocular surgery, including laser therapy/surgery;
  • Subjects with a condition or in a situation which the investigator feels may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study.
  • Subjects unable to tolerate ophthalmic imaging;
  • Subjects who did not take off their contact lenses earlier than 15 minutes prior to the study;
  • Subjects with corneal or conjunctival abnormalities that may affect adequate assessment of the anterior chamber in either eye;
  • Subjects that present with an active ocular infection in either eye;
  • Subjects who have a history of ocular surgery, including laser therapy/surgery;
  • Subjects with a condition or in a situation which the investigator feels may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study.
  • Subjects unable to tolerate ophthalmic imaging;
  • Subjects who did not take off their contact lenses earlier than 15 minutes prior to the study;
  • Subjects with corneal or conjunctival abnormalities that may affect adequate assessment of the anterior chamber in either eye;
  • +5 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

NorthEast Eye Research Associates

Woburn, Massachusetts, 01801, United States

RECRUITING

MeSH Terms

Conditions

CataractAphakiaPseudophakia

Condition Hierarchy (Ancestors)

Lens DiseasesEye DiseasesSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Ioanis Panagiotopoulos, Dr.

    NorthEast Eye Research Associates

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
OTHER
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 12, 2023

First Posted

October 3, 2023

Study Start

June 23, 2023

Primary Completion

October 31, 2023

Study Completion

October 31, 2023

Last Updated

October 3, 2023

Record last verified: 2023-09

Locations